Novo Nordisk A/S
The purpose of this study is to learn more about NNC0662-3168 as a potential treatment for people living with overweight or obesity and/or type 2 diabetes(T2D). The study will investigate its safety, tolerability and its effects in the body. The study will be conducted in four parts. Part A: Single Ascending Dose, Part B: Multiple Ascending Dose: Part C: Dose-finding in Weight Management. Part D: T2D proof-of-concept.
Inclusion Criteria: Male or female (sex at birth). * Age at the time of signing the informed consent: * For Part A: 18-55 years (both inclusive). * For Part B: 18-55 years (both inclusive). * For Part C: 18-65 years (both inclusive). * For Part D: 18-75 years (both inclusive). Part D : * Diagnosed with type 2 diabetes mellitus \>= 120 days before screening. * Treatment-naive to antidiabetic drugs, or on stable daily dose(s) \>= 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metfo…
NNC0662-3168 is administered subcutaneously.
Placebo is administered subcutaneously.
Active Comparator is administered subcutaneously.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.